Drug Discovery World

MAY 15, 2024

Researchers have developed a new vaccine technology that can provide protection against a broad range of coronaviruses with potential for future disease outbreaks – including ones we don’t know about yet. Building protective vaccines before a pandemic emerges “We don’t have to wait for new coronaviruses to emerge.

Vaccination 52

Vaccination Vaccine Immune Response Clinical Trials 52

Scienmag

JANUARY 28, 2022

ATLANTA—An influenza vaccine administered through the nose and constructed with nanoparticles that enhance immune response offers strong protection against different influenza virus strains, according to researchers in the Institute for Biomedical Sciences at Georgia State University.

Immune Response 95

Immune Response Vaccination Vaccine Research 95

pharmaphorum

SEPTEMBER 7, 2020

A trial of Russia’s Sputnik V coronavirus vaccine has shown the jab produces an immune response, although the study was too small to produce conclusive findings, particularly on safety. The vaccine also produced a T-cell response within 28 days, a secondary outcome.

Immune Response 93

Immune Response Vaccination Vaccine Trials 93

Pharmaceutical Technology

NOVEMBER 25, 2022

XtalPi has entered a strategic partnership with CK Life Sciences for artificial intelligence (AI)-driven tumour vaccine research and development (R&D). Under the collaboration, the companies will utilise their capabilities to co-develop a new AI tumour vaccine R&D platform.

Life Science 246

Life Science Vaccination Vaccine Development 246

The Pharma Data

OCTOBER 26, 2020

AstraZeneca’s COVID-19 vaccine candidate, AZD1222, elicited immune responses in older coronavirus patients similar to ones generated in younger adults, lending more promise to a vaccine that’s seen as one of the leading contenders in the race to become the first approved COVID-19 vaccine. Source link.

Immune Response 52

Immune Response Vaccination Vaccine Research 52

Pharmaceutical Technology

AUGUST 1, 2022

GreenLight Biosciences has entered a partnership with the US National Institutes of Health (NIH) for the development of Covid-19 vaccines, which offer broader protection against new variants and with durable effects. They intend to develop vaccines that provide lasting immune responses compared to existing vaccines.

Vaccination 245

Vaccination Vaccine Development RNA 245

Pharmaceutical Technology

OCTOBER 14, 2022

German pharmaceutical firm Merck has extended its partnership with Moderna to jointly develop and sell mRNA-4157/V940, an investigational personalised cancer vaccine (PCV). They subsequently expanded the collaboration to include the development of antigen mRNA cancer vaccines in 2018.

Vaccination 289

Vaccination Vaccine Development Immune Response 289

The Pharma Data

DECEMBER 4, 2021

The first peer-reviewed study in North America examining the timing between the first and second doses of COVID-19 mRNA vaccines shows that a longer dose interval leads to a stronger immune response. The study is funded by the Government of Canada through its COVID-19 Immunity Task Force (CITF).

Immune Response 52

Immune Response Vaccination Vaccine Antibody 52

Medical Xpress

MARCH 29, 2023

Researchers have found that, despite being heavily immunocompromised, hematology patients generate strong cellular immune responses against SARS-CoV-2 after vaccination, on par with that of healthy individuals.

Immune Response 126

Immune Response Vaccination Vaccine Research 126

Pharmaceutical Technology

JUNE 23, 2022

The US Food and Drug Administration (FDA) has granted approval for Merck's (MSD outside the US and Canada) pneumococcal 15-valent conjugate vaccine, Vaxneuvance, for use in children aged six weeks to 17 years. The post US FDA grants approval for Merck’s pneumococcal vaccine for children appeared first on Pharmaceutical Technology.

Vaccination 147

Vaccination Vaccine Immune Response Clinical Trials 147

Drug Discovery World

MAY 2, 2024

A study led by the University of Oxford has successfully investigated human immunity against Covid-19 in people who already have antibodies, with the aim of advancing future vaccines and treatments. The results suggest that previous infection, together with vaccination, offers strong protection against the original Covid-19 strain.

Vaccination 59

Vaccination Vaccine Development Immune Response 59

Pharma Times

DECEMBER 20, 2023

The Novo Nordisk Foundation has committed $260m to establish a new state-of-the-art research and vaccine development initiative to help combat deadly airborne infections. The initiative aims to create new or improved vaccines for deadly respiratory diseases, including tuberculosis (TB) and influenza. million deaths every year.

Vaccination 86

Vaccination Vaccine Immune Response Bacteria 86

Pharmaceutical Technology

FEBRUARY 3, 2023

Only a few weeks into the new year, the prospect of getting a successful advanced HIV vaccine shrank after the discontinuation of yet another late-stage trial. On January 18, Janssen, a Johnson & Johnson (J&J) subsidiary, stated that its vaccine was not effective in preventing HIV infections.

Vaccination 293

Vaccination Vaccine Antibody Trials 293

Pharmaceutical Technology

MARCH 20, 2023

RVAC Medicines has announced a research collaboration with the University of Pennsylvania (Penn) for the discovery and development of mRNA vaccines. The mRNA vaccine candidates will help reduce the chances of autoimmune responses that might lead to allergic conditions or serious autoimmune diseases.

Vaccination 245

Vaccination Vaccine Development Allergies 245

The Pharma Data

OCTOBER 22, 2020

AstraZeneca’s COVID-19 vaccine candidate, AZD1222, currently being evaluated in phase 3 global trials, delivers a strong immune response, according to a new UK study. Source link.

Immune Response 52

Immune Response Vaccination Vaccine Trials 52

Scienmag

MARCH 10, 2022

Close interactions with infectious disease set both University of California, Santa Cruz graduate student Ana Nuñez Castrejon and Associate Professor of Biomolecular Engineering Rebecca DuBois on the path of studying Respiratory syncytial virus (RSV), a common and sometimes dangerous respiratory disease for which there is not currently a vaccine.

Immune Response 77

Immune Response Vaccination Vaccine Protein 77

Medical Xpress

DECEMBER 5, 2022

Research by RCSI University of Medicine and Health Sciences has provided new insights into the mechanism behind how our circadian 24-hour body clock influences our immune response to vaccines, depending on the time of day.

Vaccination 75

Vaccination Vaccine Immune Response Research 75

pharmaphorum

MARCH 15, 2021

MeMed CEO Dr. Eran Eden explores the relationship between the host immune response and SARS-CoV-2 infection and how technology could help personalise treatment strategies. This is made possible using ‘Advanced Host Immune Response Technologies’. The pace of work in the industry reached almost ludicrous speeds.

Immune Response 65

Immune Response Vaccination Vaccine Development 65

BioTech 365

OCTOBER 21, 2020

Biotechnology, Pharma and Biopharma News – Research – Science – Lifescience ://Biotech-Biopharma-Pharma: GSK sees ‘robust immune response’ from RSV vaccine hopefuls.GSK sees ‘robust immune response’ from RSV vaccine hopefuls badams Wed, 10/21/2020 – 04:07 from FierceBiotech: Biotech [link].

Immune Response 40

Immune Response Vaccination Vaccine Research 40

pharmaphorum

OCTOBER 11, 2022

An intranasal formulation of AstraZeneca’s widely-used COVID-19 vaccine Vaxzevria has failed at the first hurdle, after results from a phase 1 trial found it was unable to stimulate a strong immune response to the virus. Other efforts to develop a nasally-delivered COVID-19 vaccine have met with greater success.

Vaccination 115

Vaccination Vaccine Immune Response Development 115

BioTech 365

SEPTEMBER 30, 2020

Biotechnology, Pharma and Biopharma News – Research – Science – Lifescience ://Biotech-Biopharma-Pharma: Moderna’s COVID-19 vaccine spurs immune response in older adults.Moderna’s COVID-19 vaccine spurs immune response in older adults ntaylor Wed, 09/30/2020 – 06:26 from FierceBiotech: Biotech [link].

Immune Response 40

Immune Response Vaccination Vaccine Research 40

BioTech 365

MAY 10, 2021

Biotechnology, Pharma and Biopharma News – Research – Science – Lifescience ://Biotech-Biopharma-Pharma: COVID-flu combo vaccine from Novavax sparks immune response to both viruses in animals.COVID-flu combo vaccine from Novavax sparks immune response to both viruses in animals arlene.weintraub Mon, … Continue reading → (..)

Immune Response 40

Immune Response Vaccination Vaccine Research 40

Medical Xpress

NOVEMBER 8, 2022

New research presented this week at ACR Convergence 2022, the American College of Rheumatology's annual meeting, showed that a higher dose of pneumococcal vaccine safely and effectively improved antibody response in patients receiving rituximab for ANCA-associated vasculitis.

Immune Response 67

Immune Response Vaccination Vaccine Antibody 67

Medical Xpress

JANUARY 30, 2023

A newly published paper in The Lancet shows that an experimental vaccine against Marburg virus (MARV) was safe and induced an immune response in a small, first-in-human clinical trial.

Vaccination 104

Vaccination Vaccine Immune Response Allergies 104

pharmaphorum

NOVEMBER 25, 2022

Scientists in the US say they have developed an mRNA-based vaccine that encompasses all 20 known subtypes of influenza that could form the basis of a future universal jab. The goals of the programme are also similar to those in COVID vaccine development.

Vaccination 105

Vaccination Vaccine Research Immune Response 105

Pharma Times

JULY 18, 2021

Studies showed immunosuppression appeared to weaken immune responses to COVID-19 vaccines

Immune Response 123

Immune Response Vaccination Vaccine Research 123

Medical Xpress

MARCH 3, 2023

A preclinical study evaluating a Kiwi-made COVID-19 vaccine—Kiwi Vax—has shown its unique formulation induces a safe and highly effective immune response to SARS-CoV-2 variants of concern, making it a promising booster vaccine candidate.

Vaccination 105

Vaccination Vaccine Immune Response Research 105

pharmaphorum

MAY 19, 2022

Moderna has joined forces with non-profit organisation IAVI on a third phase 1 trial of its candidate HIV vaccine in Africa, where the burden of the virus is still being keenly felt. There are hopes that its mRNA approach, which proved so effective against COVID-19, could succeed where traditional vaccine technologies have failed in HIV.

Vaccination 145

Vaccination Vaccine Trials Immune Response 145

Pharma Times

JUNE 29, 2021

Mixing different vaccines produces a strong immune response against virus, according to researchers

Immune Response 127

Immune Response Vaccination Vaccine Research 127

BioSpace

NOVEMBER 7, 2022

Researchers from the University of Washington have developed an investigational vaccine that can safely elicit an immune response against the HER2 protein, a key marker in breast cancer.

Immune Response 94

Immune Response Vaccination Vaccine Protein 94

BioTech 365

SEPTEMBER 9, 2020

Biotechnology, Pharma and Biopharma News – Research – Science – Lifescience ://Biotech-Biopharma-Pharma: Pfizer, BioNTech report ‘strong’ immune response in animals to COVID-19 mRNA vaccine candidate.Pfizer, BioNTech report ‘strong’ immune response in animals to COVID-19 mRNA vaccine candidate arlene.weintraub Wed, … Continue (..)

Immune Response 40

Immune Response Vaccination Vaccine Research 40

XTalks

FEBRUARY 19, 2024

Moderna has been testing an experimental mRNA vaccine aimed at combating the human cytomegalovirus (CMV), which poses significant health risks to newborns and immunocompromised patients. The team used the data and patient samples from a gB/MF59 Phase II trial in adolescent girls as a benchmark to assess the new mRNA-based vaccine.

Vaccination 59

Vaccination Vaccine Trials Clinical Trials 59

BioTech 365

NOVEMBER 2, 2020

Biotechnology, Pharma and Biopharma News – Research – Science – Lifescience ://Biotech-Biopharma-Pharma: CureVac links COVID-19 vaccine to immune response, setting it up to enter pivotal trial.CureVac links COVID-19 vaccine to immune response, setting it up to enter pivotal trial … Continue reading →

Immune Response 40

Immune Response Vaccination Vaccine Trials 40

Pharmaceutical Technology

DECEMBER 6, 2022

Evaxion Biotech and ExpreS 2 ion Biotechnologies have entered a vaccine discovery collaboration agreement to co-develop a new cytomegalovirus (CMV) vaccine candidate. Until 2025, the companies will equally share the research and intellectual property licensing expenses under the partnership.

Vaccination 130

Vaccination Vaccine Development Immune Response 130

The Pharma Data

SEPTEMBER 10, 2020

Pfizer-BioNTech announced Wednesday that preliminary preclinical data from mouse and macaque monkey models showed a strong immune response from its mRNA COVID-19 vaccine. . Tareq Aziz Touhid. The study and the data are currently subject to peer review.

Immune Response 52

Immune Response Vaccination Vaccine RNA 52

BioSpace

OCTOBER 14, 2021

Every week there are numerous scientific studies published. Here’s a look at some of the more interesting ones.

Immune Response 90

Immune Response Vaccination Vaccine Research 90

Pharmaceutical Technology

FEBRUARY 15, 2023

In the last three years alone, there have been over 633,000 patents filed and granted in the pharmaceutical industry, according to GlobalData’s report on Innovation in Pharmaceuticals: Coronavirus vaccine components. The vaccine also contains other inactive ingredients such as cholesterol.

Vaccination 130

Vaccination Vaccine Containment Immune Response 130